Sword Bio has optimized a number of proprietary assays to support the analysis of anti-drug antibodies (ADAs) with significantly improved sensitivity, precision, and performance. If you would like to obtain an assay as a customized solution for your ADA project, you can request more information here.
In response to our client’s needs, Sword Method Development Scientists have developed our proprietary Nuc-Cyte™ DNA-Binding Platform for the identification and quantitation of cellular transcription factors.
Transcription factors (TFs) are cellular proteins that regulate the transcription of DNA by binding to specific nucleic acid regulatory sequences within genes.
Their role in the regulation of gene expression is critical to fundamental cellular processes, such as cell differentiation, development, growth, replication, survival, and death.
To promote the accurate and precise detection and quantitation of TFs, we developed the Nuc-Cyte™ Platform for DNA Binding Assays (the Nuc-Cyte™ Platform). The Nuc-Cyte™ Platform consists of:
Nuc-Cyte™ DNA-binding immunoassays are:
Contact us today to discuss how our proprietary Sword Swift™ Method Development Process, Sword Swift™ Detection Reagents, and our scientific method development expertise can be utilized to speed your drug or diagnostic assay development processes.